Food and Behaviour Research

Donate Log In

N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease

Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, Zhong L, Bowens BK, Chervoneva I, Intenzo C, Newberg AB (2019) Clin Pharmacol Ther.  2019 Jun.  doi: 10.1002/cpt.1548. [Epub ahead of print] 

Web URL: Read this and related abstracts on PubMed here

Abstract:

This study assessed the biological and clinical effects in patients with Parkinson's disease (PD) of N-acetyl-cysteine (NAC), the prodrug to l-cysteine, a precursor to the natural biological antioxidant glutathione.

Forty-two patients with PD were randomized to either weekly intravenous infusions of NAC (50 mg/kg) plus oral doses (500 mg twice per day) for 3 months or standard of care only. Participants received prebrain and postbrain imaging with ioflupane (DaTscan) to measure 
dopamine transporter (DAT) binding. In the NAC group, significantly increased DAT binding was found in the caudate and putamen (mean increase from 3.4% to 8.3%) compared with controls (P < 0.05), along with significantly improved PD symptoms (P < 0.0001). The results suggest NAC may positively affect the dopaminergicsystem in patients with PD, with corresponding positive clinical effects.

Larger scale studies are warranted.

FAB RESEARCH COMMENT:

See the associated news article: